Full-Time

Head of Formulation and Drug Product Development

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

CA$164.8k - CA$247.2kAnnually

+ Equity + Annual Bonus

Senior, Expert

Vancouver, BC, Canada

Category
Public Health
Biology Lab & Research
Biology & Biotech

You match the following AbCellera Biologics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 12-15+ years of industry experience with a PhD in a relevant scientific discipline. Strong candidates with BSc or MSc degrees may be considered with sufficient Process Development and leadership experience
  • 6+ years of experience building, leading, and developing a cross-functional team
  • Experience in establishing and running a Formulation Development team for monoclonal antibodies and other protein biologics
  • Experience establishing phase-appropriate first-in-human formulation development strategies, including stability evaluation, biophysical characterization, and clinical in-use evaluation
  • Experience overseeing the execution of formulation and drug product development activities at CDMO partner sites
  • Experience in working closely with Quality teams to establish workflows that enable successful documentation, data capture, and data integrity, ensuring compliance with industry standards
  • Deep knowledge of global regulatory expectations for the development of protein biologics, including experience supporting INDs, CTAs, and other regulatory filings. Direct experience interacting with regulatory agencies and health authorities is desired
  • Bias towards innovation over industry standards, keen to do things differently, and passionate about building dynamic teams and capabilities that accomplish important goals
  • Strongly self-motivated and able to identify project needs and follow that up with building and implementing solutions
  • Experience with device development and/or antibody-drug conjugates
Responsibilities
  • Further developing the overall strategy for all aspects of formulation, drug product, and clinical in-use development for therapeutic antibodies
  • Developing the formulation and drug product team and workflows to deliver appropriate formulations and drug products for AbCellera’s pipeline
  • Supporting and providing strategic guidance to meet near and long term clinical demands with a network of CMOs and CDMOs, as needed
  • Providing a beginning-to-end solution for all aspects of antibody formulation development
  • Working closely with AbCellerites to develop an innovative approach to CMC development that is closely integrated with our antibody discovery and development workflows
  • Developing workflows for screening and selecting lead antibody molecules with optimal developability and manufacturing properties
  • Preparing regulatory documents and communicating with health authorities
  • Continuously driving improvements to the established processes, increasing speed and efficiency while meeting regulatory requirements
Desired Qualifications
  • Experience with device development and/or antibody-drug conjugates

AbCellera focuses on discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera excels at addressing challenging targets that traditional methods struggle with. The company's goal is to advance new treatments to market while generating revenue through partnerships, discovery services, and licensing its antibody candidates.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Biogen could solve the blood-brain barrier challenge in neuroscience.
  • Partnerships with Viking and ArrowMark may diversify revenue and enhance market presence.
  • Expanded collaboration with Eli Lilly could advance immunology, cardiovascular, and neuroscience programs.

What critics are saying

  • Increased competition in T-cell engagers may impact AbCellera's market share.
  • Failure in Biogen collaboration could harm reputation and financial outcomes.
  • Peter Thiel's resignation may lead to strategic shifts affecting investor confidence.

What makes AbCellera Biologics unique

  • AbCellera excels in antibody discovery with a proprietary, integrated technology platform.
  • The company partners with leading firms like AbbVie and Eli Lilly for drug development.
  • AbCellera's focus on multiomics and AI enhances its drug discovery efficiency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Stock Titan
Jan 13th, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022.

North Carolina Biotechnology Center
Sep 30th, 2024
Dualogics Sells Antibody Platform to Canadian Company | North Carolina Biotechnology Center

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Stock Titan
Jul 31st, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs.

Securities.io
Jun 13th, 2024
Top 10 Biotech Big Data Companies

More Data For Better MedicineThe more we learn about biology, the more we realize all we do not know. It started with the genomic revolution and the first human genome sequenced in the early 2000s.Genomics has now been joined by other datasets like transcriptomics, proteomics, metabolomics, microbiome, etc. forming a new “multiomics” science. We discussed in further detail this evolution in “ Multiomics Are The Next Step In Biotechnology ”.These new tools have created a flood of data bringing detailed information about the inner activities of cells sometimes down to the atomic level. A key driver of this data growth has been the collapse of price of sequencing gene and other biological materials like proteins.This has created enthusiasm about “Big Data” potential in biotech, mimicking the concept of big data from other, more IT-driven fields.Already in 2018, the magazine Barron’s was asking “ Will Big Data Lead to Big Biotech Returns? ” and the industry started to ask “ Implementing Large-Scale Data Processing and Analysis for Bioprocessing ”Quite a few companies are well-positioned to benefit from the drive to create and analyze at-scale biological data.AI Merging With Big Data?A new development in the last few years has been the emergence of AI. While AI made its way into public consciousness mostly in 2023, with LLMs (Large Language Models) like ChatGPT, the biotech industry started to embrace AI many years before that.And it makes sense because data and AI have a somewhat symbiotic relationship:Training AI models requires a lot of data with high quality and annotations.AIs can help sort out massive datasets without direct human intervention and connect the dots where manual analysis would not be possible.The result is that today, a lot of the previously big data-focused companies in the biotech industry are also turning into AI companies.Contrary to some AI applications still looking for a business model (like image generation), drug discovery and medical research have a pretty straightforward path from AI model to monetization.Top 10 Big Data Biotech StocksIllumina is the leading genomics company, by far the largest and most established in the industry, with $1.2B in revenues, which grew 11% CAGR in the last 5 years.This also makes it the prime provider of genomic data to the entirety of the biotech industry.Like most genome sequencing companies, Illumina makes money when selling sequencers but mostly when selling the consumables used by the sequencers

Seeking Alpha
May 1st, 2024
AbCellera partners with PE firms to develop antibody drugs, company creation

AbCellera (NASDAQ:ABCL) has inked an agreement with Viking Global Investors and ArrowMark Partners to develop new antibody drug programs, with an initial focus on immunology.